Spanish oncology research outfit Medica Scientia Innovation Research (MEDSIR) is infusing artificial intelligence into its breast cancer trials through a collaboration with Ataraxis AI, with the goal of finding new ways to predict patient outcomes and personalize cancer care.
MEDSIR will use the Ataraxis Breast platform developed by the New York AI company, which combines pathology results and clinical data to forecast how patients will respond to different treatments, including antibody-drug conjugates and CDK4/6 inhibitors, according to an Oct. 2 release.
“Breast cancer treatment continues to improve, with new therapies becoming available every year. However, this creates a challenge in selecting the right drug at the right time,” Ataraxis CEO and co-founder Jan Witowski, M.D., Ph.D., said in the release. “We are proud to partner with MEDSIR to validate our breast cancer platform using data from practice-changing clinical trials.”
MEDSIR’s trials in turn give Ataraxis access to data from more than 1,000 breast cancer patients. The ultimate goal is to improve clinical decision-making, according to the companies.
“Partnering with Ataraxis AI allows us to integrate cutting-edge artificial intelligence into clinical trials, generating evidence that can transform treatment decision-making in breast cancer,” MEDSIR’s scientific director Alicia García, Ph.D., said in the release.
With offices in Barcelona and Cambridge, Massachusetts, MEDSIR also expanded its reach into South America through a 2022 partnership with Goldman Sachs-backed Oncoclínicas, a Brazilian oncology research chain.